Introduction {#s1}
============

*Fructus aurantii* (FA), also called Zhiqiao in Chinese, refers to the dried unripe fruit of *Citrus* × *aurantium* L. or its cultivar (Rutaceae). FA is a very important Qi-invigorating herb in China for thousands of years, and it vigorously modulates the motion of Qi and fortifies the spleen and stomach ([@B3]). Modern pharmacological researches have established that FA possesses astoundingly biomedical properties, such as prokinetic effect ([@B24]; [@B40]), antidepression activity ([@B30]), anti-inflammation function ([@B21]), anticarcinogenic activity ([@B22]), antihepatotoxicity ([@B25]), antihypersensitivity ([@B11]), and hypoglycemic and hypolipidemic effects ([@B10]). It is well known that the primary chemical compositions in FA are flavonoids, alkaloids, volatile oils, and coumarins ([@B14]). In which the main bioactive compounds are considered to be naringin, neohesperidin, meranzin hydrate (MH), meranzin, Naringenin, hesperetin nobiletin, tangeretin, and auraptene ([@B24]; [@B35]; [@B14]; [@B29]; [@B39]; [@B2]).

The therapeutic effects of a drug and its components are closely related to their pharmacokinetic characteristics. The pharmacokinetics of naringin and/or neohesperidin have been extensively studied in rats ([@B5]; [@B4]; [@B13]; [@B12]; [@B37]), dogs ([@B18]), rabbits ([@B6]), and human beings ([@B8]; [@B9]; [@B1]). Multi-component pharmacokinetics can also be accessible for several flavones in FA ([@B27]; [@B29]; [@B39]). Very recently, the comparative pharmacokinetics of naringin and neohesperidin between different model rats ([@B32]) and different herbs ([@B15]) have been reported. As a whole, the above pharmacokinetic evaluation mainly focused on pure monomers (mainly flavones) ([@B8]; [@B9]; [@B5]; [@B6]; [@B4]; [@B18]; [@B13]; [@B12]), the extract of a single herb ([@B27]; [@B29]; [@B39]), or the study of the pharmacokinetic interaction between two or more herbs ([@B15]; [@B32]). Few pharmacokinetic data can be accessible for the other compounds, such as MH, meranzin, and nobiletin.

Our previous study indicated that the components (MH, meranzin, and nobiletin) have good physiological activity with relatively high abundance in FA besides naringin and neohesperidin. We also found that the drug quality is closely related to the content proportion of naringin *vs* neohesperidin in FA, which can partly elucidate the geo-authentic origin of the medicinal plant ([@B2]). So, it is interesting to investigate the pharmacokinetic differences of naringin and neohesperidin between the different forms (monomer, compatibility, and extract).

Some literatures indicated that naringin and neohesperidin transiently exist in the plasma, and the glucuronides/sulfates of their aglycones (naringenin and hesperetin) were the main circulating metabolites ([@B5]; [@B4]; [@B32]). Free naringenin and hesperetin can be easily obtained from the naringenin-glucronaide and hesperetin-glucronaide in plasma by hydrolysis with *β*-glucuronidase and sulfatase. In addition, naringenin and hesperetin are relatively low content in FA. So, the concentration of the absorbed naringin and neohesperidin can be detected in the corresponding aglycone form (naringenin and hesperetin).

Hence, a rapid and sensitive ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the simultaneous determination of the main components (naringin, neohesperidin, MH, meranzin, and nobiletin) in rat plasma, and used for the pharmacokinetic study of the compounds in different forms: monomer, compatibility, and extract.

Materials and Methods {#s2}
=====================

Crude Drugs {#s2_1}
-----------

*Fructus aurantii*, the dry immature fruit of *Citrus × aurantium* L., were provided by Jiangxi Zhihui Chinese Medicinal Materianls Co. Ltd. The coordinates of plant picking is 115.226067 East longitude and 28.030638 North latitude (Wucheng Town, Zhangshu, Jiangxi, China). The crude drugs were identified as *Citrus junos* Sieb. ex Tanaka by Professor Wuliang Yang from Jiangxi University of Traditional Chinese Medicine (JXUTCM), China. Voucher specimens are preserved in the Herbarium of Pharmacognosy in JXUTCM.

Chemicals and Reagents {#s2_2}
----------------------

Standards including neohesperidin, naringin, meranzin hydrate, naringenin, hesperetin, meranzin, and nobiletin were purchased from Chengdu Desite Biotech Co., Ltd. (Chengdu, China), and their purities were not lower than 98% according to HPLC analysis. Quercetin (Internal standard, IS) (HPLC ≥ 98%) was purchased from Chengdu Mansite Pharmaceticcal Co., Ltd. (Chengdu, China). *β*-glucuronidase and sulfate esterase were purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China), Formic acid was purchased from Shanghai Aladdin Bio-Chem Technology Co. Ltd. (Shanghai, China). Chromatographic reagent Methanol (Merck, Germany) and acetonitrile (Tedia, USA) were used throughout. Deionized Water was purified by Milli-Q purification system (Millipore, MA, USA). All other chemical regents were of analytical grade.

Apparatus and UPLC--MS/MS Conditions {#s2_3}
------------------------------------

The UPLC-MS/MS system consisting of Shimadzu Ultra-High Performance Liquid Chromatograph LC-30A and Triple Quadrupole Mass Spectrometer (LCMS-8050, SHIMADZU, Japan).

### Liquid Chromatography {#s2_3_1}

The chromatographic separation was achieved on an Agilent C~18~ column (2.1x100mm, 1.8μm, Agilent, United States) with temperature at 40°C; The mobile phase was composed of water (containing 0.1% formic acid) (solvent A) and Acetonitrile (solvent B). The gradient elution procedures (0.01--5 min, 30 to 50% B, 5--7min, 50% B, 7--7.5min, 50--30% B, 7.5--10.5min, 30% B); The flow rate was 0.3 ml/min and injection volume was 1.0 μl ([@B36]).

### Mass Spectrometry {#s2_3_2}

The mass spectrometer was operated in negative mode for quercetin (IS), naringenin, and hesperetin, and positive mode for meranzin hydrate, meranzin, nobiletin. Quantification was obtained using multiple reaction monitoring (MRM) mode in the following positive/negative MS/MS scan segments. Segment I: 1.5--2.3min in positive mode, meranzin hydrate; Segment II: 2.2--4.5min in negative mode quercetin (IS), naringenin, and hesperetin; Segment III: 4.4--7.5min in positive mode for meranzin and nobiletin. The optimal MS parameters were as follows: Interface ESI, Nebulizing Gas Flow of 3.0 L/min; Heating Gas Flow of 10 L/min; Interface Temperature of 300°C; DL Temperature of 250°C; Heat Block Temperature of 400°C; Drying Gas Flow of 10 L/min; Nebulizing Gas of 3.0 L/min, Drying Gas F1 of 10.0 L/min, Conversion Dy: 10 kV, Detector Volt: 1.92 kV. MS/MS operating conditions were optimized by infusion of the standard solution (200 ng/ml) of each analyte and I.S. into the ESI source *via* a syringe pump. The optimal MRM parameters for these compounds are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

MRM detection parameters for the five components and IS.

  Components         Precursor ion   Q~1~ (V)   Collision energy (eV)   Q~3~ (V)   Product ion
  ------------------ --------------- ---------- ----------------------- ---------- -------------
  Meranzin hydrate   279.10          -13.00     -33.00                  -25.0      131.10
  Naringenin         271.10          13.00      18.00                   14.00      151.05
  Hesperetin         301.05          15.00      24.00                   15.00      164.05
  Meranzin           261.10          -12.00     -29.00                  -26.0      131.10
  Nobiletin          403.15          -18.00     -28.00                  -27.00     373.10
  Quercetin (IS)     301.10          14.00      22.00                   13.00      151.00

Animals {#s2_4}
-------

Male Sprague-Dawley (SD) rats \[Certificate No. SCXK(Xiang) 2016-0002\] weighing 200 ± 20 g were purchased from Hunan Silaike Laboratory Animal Ltd (Changsha, China). The animals were kept in a controlled breeding room with the following conditions: a temperature of 22 ± 2°C, a relative humidity of (65 ± 5)%, and a 12 h light- dark cycle ([@B36]). The Experimental Animal Ethic Committee of JXUTCM approved all animal protocols. The animal experiments were carried out according to the European Community guidelines for the use of experimental animals.

Sample Preparation {#s2_5}
------------------

### Preparation of FA Extract {#s2_5_1}

The dried drug was extracted twice by refluxing with boiling Methanol (1:10, w/v) for 2 h, then the two filtrates were merged and evaporated to dryness under vacuum ([@B27]). The extract (14.56 g) was weighed and the extract yield was 29.14%. The obtained extract was stored at 4 °C until use. To count the dosage, the contents of the main compounds in the FA extract were quantitatively measured by HPLC ([@B39]; [@B2]), and the contents of naringin, neohesperidin, meranzin hydrate, meranzin and nobiletin in the extract were 171.6, 167.5, 1.98, 0.94, and 1.70 mg/g raw herb, respectively (see supplementary material: [**Figure S1**](#SM1){ref-type="supplementary-material"}).

### Preparation of Calibration Standards and Quality Control (QC) Samples {#s2_5_2}

The stock solutions of the mixed standards were prepared in methanol with the concentrations of meranzin hydrate (194 µg/ml), naringenin (491 µg/ml), hesperetin (494 µg/ml), meranzin (209 µg/ml), nobiletin (528 µg/ml), and quercetin (IS) (303 µg/ml). All solutions were stored at 4 °C. The concentrations of each analyte in standard mixture solutions were as follows: 19.4 µg/ml for meranzin hydrate, 14.73 µg/ml for naringenin, 12.35 µg/ml for hesperetin, 4.18 µg/ml for meranzin, and 2.112 µg/ml for nobiletin. Then, the standard mixture solution was diluted to a series of concentration (1/2, 1/5, 1/10, 1/20, 1/50, 1/100, 1/250, 1/500, 1/1,000, and 1/2,000) as calibration curves. QC samples were prepared at three concentration levels containing meranzin hydrate (19.4, 388, and 19,400 ng/ml), naringenin (14.73, 294.6, and 14,730 ng/ml), hesperetin (12.35, 247, and 12,350 ng/ml), meranzin (4.18, 83.6, and 4,180 ng/ml), and nobiletin (2.112, 42.2, and 2,112 ng/ml). These samples were stored at −80°C until analysis.

### Biological Sample Preparation {#s2_5_3}

The 20 μl of *β*-glucuronidase and 15 μl of sulfatase were added into 50 μl of plasma sample. After vortexed for 30 s, the mixture was incubated at 37°C for 2 h in a water bath, then placed in ice water for 5 min to terminate the reaction ([@B32]). IS solution (20 µl, 5 μg/ml) and acetonitrile (1.0 ml) were added into the mixture and vortexed for 2 min. The mixture was centrifuged at 4,000 rpm at 4°C for 10 min, and the supernatant (850 µl) was transferred into a new eppendorf tube and evaporated to dryness. The residue was redissolved in 100 μl of 50% methanol, and vortexed for 3 min, then centrifuged at 14,000 rpm at 4°C for 10 min, finally the supernatant was used for UPLC-MS/MS analysis.

Method Validation {#s2_6}
-----------------

This method was validated according to the current US FDA Bioanalytical Method Validation Guidance (Guidance for Industry: Bioanalytical Method Validation, 2001). The following parameters were determined: selectivity, linearity, LLOQ, LOD, precision, accuracy, extraction recovery, matrix effect, and stability.

### Linearity Parameters {#s2_6_1}

To assess the linearity ranges, a series of the mixed standard solutions (six concentration levels) were prepared in triplicate. Each calibration curve (y = ax + b) was established by plotting the peak area ratio of analyte to IS (y) against the concentrations (x) of the calibration solution with a least square linear regression. The limit of detection (LOD) and limit of quantification (LOQ) were determined when the peak height was three times and ten times the background noise, respectively ([@B36]).

### Specificity and Selectivity {#s2_6_2}

Blank plasma samples or the samples spiked with the IS were detected for endogenous or IS interference ([@B39]). Specificity and selectivity were investigated by comparing the chromatograms of five individual batches of blank plasma samples, the samples spiked with the 5 analytes and IS, and plasma samples at 0.75 h after oral administration of FA extracts.

### Accuracy and Precision {#s2_6_3}

The intra- and inter-day precisions and accuracies were calculated by an analysis of variance based on the replicate analysis of QC samples, and the work was accompanied by a standard calibration curve on each analytical run ([@B36]). Five samples were measured for each concentration level on the optimal conditions five times within the same day for intra-day variance, and the three different days for inter-day variance. The analytic precision was denoted as the RSD (relative standard deviation), and the accuracy was considered the RE (relative error) of the measured average deviated from the nominal value. The precision and accuracy values (RSD%) were required to be within ±20% for LLOQ (lower limit of quantification) and within ±15% for other concentrations.

### Extraction Recovery and Matrix Effect {#s2_6_4}

The extraction recoveries of the compounds were assessed by comparing the mean peak areas from five plasma samples in the pre-extraction spiked with the analytes and the post-extraction at three QC levels. The matrix effects were evaluated by comparing the peak areas obtained from the spiked plasma matrix with the pure standard solutions at the same concentrations. There was no matrix effect if the ratio was between 85--115%.

### Stability {#s2_6_5}

The QC samples were assayed under several different conditions to evaluate the stability of the compounds in rat plasma. For the short-term stability, fresh plasma samples were kept at room temperature for 24 h before the sample preparation. After keeping the samples at room temperature for 24 h, post-preparation stability was tested. Freeze-thaw cycles (-20 °C/room temperature) stability were not treated at -20°C for freezing-room temperature melting three times (repeated freezing and thawing three times). In each freeze-thaw cycle, the samples were frozen and stored at -20 °C for 24 h, and subsequently thawed at room. To evaluate the long-term stability of QC plasma samples, following storage at -20 °C for one month. The stability data were acceptable when the bias was within ±15% of the actual value ([@B36]).

Pharmacokinetics {#s2_7}
----------------

Rats were randomly divided into the following four groups (6 rats in each group): naringin (NA), neohesperidin (NHE), naringin-neohesperidin (NA-NHE), and FA extract group. The oral administration doses were selected according to the literatures ([@B27]; [@B33]; [@B3]; [@B29]; [@B39]; [@B2]), the contents of the five components in FA, and the preliminary experiments. The specific doses were as follows: FA extract (10.8 g/kg of the original medicinal material), 10 ml/kg; naringin and neohesperidin, 1.85 g/kg and 1.81 g/kg, respectively. The drug was suspended in 0.5% CMC-Na.

Blood samples (about 0.5 ml) were collected from the ocular vein using dried heparinized tubes from each six rats at 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 14.0, 24.0, and 30.0 h after dosing. The rats were intragastric administrated with 1.5 ml of water at the time points of 0.25, 0.5, 2, 4, and 6 h, respectively. The rats had free access to water during the experiment. The blood samples were then immediately centrifuged at 4,000 rpm for 10 min. The plasma was frozen and stored at −80°C until analysis.

The plasma concentration of the studied compounds was determined according to the daily calibration curve. The pharmacokinetic parameters, including C~max~ (the peak drug plasma concentration), T~max~ (the time to C~max~), AUC~(0-t)~ (the area under the plasma concentration-time curve from 0 to the last time point), AUC~(0−∞)~ (the area under the plasma concentration-time curve from 0 to time infinity), MRT~(0--t)~ (average residence time from 0 to the last time point), and t~1/2z~ (the elimination half-life) were fitted with the proprietary DAS 3.1 pharmacokinetic program (Chinese Pharmacological Society).

Statistical Analysis {#s2_8}
--------------------

All statistical analyses were performed using the SPSS 21.0 software package from SPSS, Inc. (Chicago, IL, USA). \**P* values \< 0.05, or \*\**P* values \< 0.01 was considered statistically significant difference.

Results {#s3}
=======

UPLC-MS/MS Conditions {#s3_1}
---------------------

According to the direct full-scan ESI mass spectra, the ion intensities of naringenin, hesperetin, and quercetin (IS) was higher in negative mode, and the other three compounds (meranzin hydrate, meranzin, and nobiletin) got greater sensitivity in positive mode. So, the switch scan method (ESI +/-) was used for the corresponding compounds, and the product ion mass spectra of the six compounds are shown in [**Figure 1**](#f1){ref-type="fig"}.

![Chemical structures and product ion mass spectra of Meranzin hydrate **(A)**, Quercetin (IS) **(B)**, Naringenin **(C)**, Hesperidin **(D)**, Meranzin **(E)**, and Nobiletin **(F)**.](fphar-11-00933-g001){#f1}

Based on previous work, chromatographic conditions such as the constituents and the gradient profiles of the mobile phase were further improved to adapt the separation and detection of six components in rat plasma. In addition, the optimum mobile phase was water (containing 0.1% formic acid) and acetonitrile.

Various sample preparation methods including protein precipitation with methanol and acetonitrile were investigated to obtain an efficient cleanup of the biological samples. In this work, acetonitrile was chosen as the protein precipitation agent with simplicity and efficiency.

Specificity {#s3_2}
-----------

Typical chromatograms of blank, spiked plasma and plasma samples are shown in [**Figure 2**](#f2){ref-type="fig"}. No interference was found between endogenous compounds or xenobiotics. The developed method results in six single sharp peaks at the retention time of meranzin hydrate, quercetin (IS), naringenin, hesperetin, meranzin, and nobiletin were 2.03, 2.46, 3.29, 3.63, 5.09, and 5.84 min, respectively.

![Representative multiple reaction monitoring (MRM) chromatograms of meranzin hydrate, naringenin, hesperetin, meranzin, nobiletin, and quercetin (IS) in rat plasma: **(A)** blank plasma, **(B)** blank plasma spiked with the 5 analytes and quercetin (IS), and **(C)** plasma sample collected at 0.75 h after oral administration of FA extract (10.8 g/kg) to rats.](fphar-11-00933-g002){#f2}

Linearity Parameters {#s3_3}
--------------------

The linearity parameters of the five components in rat plasma using weighed (1/x^2^) least-squares linear regression analysis are summarized in [**Table 2**](#T2){ref-type="table"}. Within the investigated linear range, good linearity data was obtained with correlation coefficients \>0.9941. The results indicate the proposed UPLC-MS/MS method has a wide linear range and high sensitivity.

###### 

Linear parameters of the compounds in rat plasma.

  Components         Calibration curves       Correlation coefficients   Range (ng/mL)     LLOQ (ng/mL)   LOD (ng/mL)
  ------------------ ------------------------ -------------------------- ----------------- -------------- -------------
  Meranzin hydrate   y = 0.001*x* + 0.0653    r^2^ = 0.9941              1.94 \~ 3880      1.94           0.59
  Naringenin         y = 0.0021*x* + 0.0383   r^2^ = 0.9981              1.473 \~ 2946     1.473          0.45
  Hesperetin         y = 0.0017*x* - 0.0031   r^2^ = 0.9994              1.235 \~ 2470     1.235          0.37
  Meranzin           y = 0.0207*x* - 0.0033   r^2^ = 0.9998              0.418 \~ 836      0.418          0.13
  Nobiletin          y = 0.0778*x* - 0.1077   r^2^ = 0.9961              0.2112 \~ 422.4   0.2112         0.06

Precision and Accuracy {#s3_4}
----------------------

The precision and accuracy results are shown in [**Table 3**](#T3){ref-type="table"}, intra-day precision was less than 7.9%, intra-day accuracy was between -8.66 to 9.68%, and inter-day precision was less than 10% for the five compounds. Inter-day accuracies were in the range of -9.34--9.94% expressed by relative errors (RE%). The relative standard deviation and relative error values did not exceed ± 15% ([**Table 3**](#T3){ref-type="table"}), this indicate the accuracy and precision are acceptable.

###### 

Intra-day and inter-day precisions and accuracies of the analytes from QC samples prepared in rat plasma (n=6).

  ---------------------------------------------------------------------------------------------------------------------
  Components         Spiked concentration\   Intra-day     Inter-day                                            
                     (ng/mL)                                                                                    
  ------------------ ----------------------- ------------- ----------- ----------------- ------------- -------- -------
  Meranzin hydrate   3.88                    3.94 ± 0.10   2.6         1.52              3.98 ± 0.24   6.0      2.65

  77.6               73.57 ± 5.77            7.8           5.19        71.38 ± 4.24      6.0           -8.01    

  3880               3557.39 ± 20.27         0.6           8.31        3517.64 ± 56.07   1.6           -9.34    

  Naringenin         2.946                   2.92 ± 0.16   5.6         -0.98             2.97 ± 0.21   7.2      0.69

  58.92              64.03 ± 3.83            6.0           8.68        63.79 ± 4.18      6.6           8.27     

  2946               2981.99 ± 39.27         1.3           1.22        2969.13 ± 58.10   2.0           0.78     

  Hesperetin         2.47                    2.62 ± 0.06   2.3         6.02              2.56 ± 0.15   5.8      3.50

  49.4               51.38 ± 3.35            6.5           4.01        50.37 ± 3.96      7.9           1.96     

  2470               2320.26 ± 10.40         0.5           -6.06       2296.49 ± 31.09   1.4           7.02     

  Meranzin           0.836                   0.78 ± 0.06   7.2         -6.18             0.76 ± 0.05   6.5      -9.27

  16.72              15.27 ± 0.72            4.7           -8.66       15.25 ± 1.00      6.6           -8.80    

  836                829.63 ± 7.05           0.9           -0.76       823.28 ± 11.34    1.4           -1.52    

  Nobiletin          0.4424                  0.41 ± 0.03   7.9         -4.01             0.42 ± 0.05   10       0.29

  8.44               9.26 ± 0.29             3.2           9.68        9.28 ± 0.44       4.8           9.94     

  422.4              410.48 ± 26.76          6.5           -2.82       376.29 ± 32.40    8.6           -10.92   
  ---------------------------------------------------------------------------------------------------------------------

Extraction Recovery and Matrix Effect {#s3_5}
-------------------------------------

The extraction recovery and matrix effect were summarized in [**Table 4**](#T4){ref-type="table"}. The recoveries were between 82.33 to 89.92%, and the matrix effects of the five compounds were in the range of 94.36--101.65%. These data indicate that the UPLC-MS/MS method provides suitable, reproducible, and reliable data and can be used as an analytical tool in rat plasma.

###### 

Extraction recovery and matrix effects of the analytes in rat plasma (n = 6).

  -------------------------------------------------------------------------------------------------------
  Components         Concentration\   Extraction recovery (%)   Matrix effect (%)                   
                     (ng/mL)                                                                        
  ------------------ ---------------- ------------------------- ------------------- --------------- -----
  Meranzin hydrate   7.76             83.44 ± 5.37              6.4                 100.28 ± 6.14   6.1

  77.6               87.89 ± 6.33     7.2                       100.94 ± 4.85       4.8             

  776                88.13 ± 3.40     3.5                       97.88 ± 4.45        4.5             

  Naringenin         5.892            82.33 ± 1.58              1.9                 94.36 ± 4.85    5.1

  58.92              86.12 ± 4.02     4.7                       98.34 ± 6.36        6.5             

  589.2              89.33 ± 1.88     2.1                       100.31 ± 4.86       4.8             

  Hesperetin         4.94             87.79 ± 4.51              5.1                 95.95 ± 7.08    7.4

  49.4               89.15 ± 6.10     6.8                       99.51 ± 4.62        4.6             

  494                88.93 ± 3.17     3.6                       98.64 ± 1.65        1.7             

  Meranzin           1.672            82.97 ± 5.88              7.1                 101.08 ± 4.97   4.9

  16.72              88.50 ± 4.46     5.0                       96.90 ± 5.39        5.6             

  167.2              88.04 ± 3.40     3.9                       98.84 ± 7.72        7.8             

  Nobiletin          0.8448           83.63 ± 0.06              7.7                 101.65 ± 6.80   6.7

  8.44               89.92 ± 1.78     2.0                       100.17 ± 6.86       6.9             

  84.48              89.85 ± 2.20     2.4                       99.16 ± 6.83        6.9             
  -------------------------------------------------------------------------------------------------------

Stability {#s3_6}
---------

The stability data under different experimental conditions are summarized in [**Table 5**](#T5){ref-type="table"}. The results showed all RSD% were less than 8.8% and RE% were in the range from -13.50 to 14.81%, which suggested that rat plasma samples containing 5 analytes were stable under routine laboratory conditions and no additional procedures were necessary to stabilize the sample for pharmacokinetic studies.

###### 

Stability of the 5 analytes in rat plasma (n = 6).

  ---------------------------------------------------------------------------------------------------------------------------------
  Components         Concentration\   Short-term Stability   Free--thaw Stability   Long-term Stability                    
                     (ng/mL)                                                                                               
  ------------------ ---------------- ---------------------- ---------------------- --------------------- ------- -------- --------
  Meranzin hydrate   3.88             7.2                    4.71                   4.6                   5.77    5.9      7.62

  77.6               1.9              1.55                   3.8                    0.71                  2.2     3.19     

  3880               0.5              7.43                   1.5                    7.63                  2.6     6.85     

  Naringenin         2.946            2.8                    -3.02                  0.3                   -4.36   7.6      -0.84

  58.92              1.2              14.81                  2.8                    8.14                  1.2     12.09    

  2946               3.9              -13.49                 3.5                    -10.94                4.2     -9.76    

  Hesperetin         2.47             7.6                    4.10                   10                    7.78    4.7      5.03

  49.4               5.6              -9.20                  5.0                    -10.70                4.3     -8.58    

  2470               8.7              -13.50                 8.0                    -12.68                5.3     -7.81    

  Meranzin           0.836            2.7                    -6.25                  1.6                   -9.71   4.9      -10.98

  16.72              13               -8.40                  1.6                    11.07                 8.8     -13.52   

  836                2.1              -2.81                  2.6                    -6.01                 5.9     -7.37    

  Nobiletin          0.4224           1.1                    7.01                   8.2                   2.21    4.9      5.83

  8.44               4.3              7.89                   2.5                    10.46                 3.9     6.71     

  422.4              0.3              0.80                   0.3                    -1.72                 1.7     -3.36    
  ---------------------------------------------------------------------------------------------------------------------------------

Pharmacokinetics {#s3_7}
----------------

The proposed UPLC-MS/MS method was applied to a multi-component pharmacokinetic study of meranzin hydrate, naringenin, hesperetin, meranzin, and nobiletin in SD rats after oral administration of the extract, NA, NHE, and NA-NHE. The plasma concentration-time profiles of the five components were shown in [**Figure 3**](#f3){ref-type="fig"}, and the corresponding pharmacokinetic parameters were shown in [**Tables 6**](#T6){ref-type="table"} and [**7**](#T7){ref-type="table"}. The physiological disposition conformed to a two-compartment model of the 5 analytes in rats fitted by the DAS 3.1 software. The results suggested that there were significant differences in pharmacokinetic parameters of naringenin and hesperetin between different drug forms, including AUC~(0--t)~, AUC~(0--∞)~, C~max~, t~max~, t~1/2z~, and CL~Z/F~. The main differences including remarkable increases in the values of AUC~(0--∞)~, AUC~(0--t)~ and C~max~, obvious decrease of CL~Z/F~, and longer t~max~ and t~1/2z~. The comparisons of C~max~ and AUC~(0--t)~ of different groups were shown in [**Figure 4**](#f4){ref-type="fig"}.

![The profiles of the mean plasma concentration over time after oral administration of the monomer (NA or NHE), the compatibility (NA-NHE), and FA extract (FA) form (mean ± SD, n = 6).](fphar-11-00933-g003){#f3}

###### 

Pharmacokinetic parameters of the 5 compounds in male SD rats after oral administration of FA extract (mean ± SD, n = 6).

  Parameter              Components                                                                    
  ---------------------- -------------------- -------------------- ------------------ ---------------- -----------------
  C~max~ (µg/L)          3356.68 ± 91.03      2448.08 ± 225.62     424.89 ± 11.13     27.74 ± 2.85     130.28 ± 4.78
  T~max~ (h)             0.96 ± 0.10          9.33 ± 1.03          9.67 ± 0.82        0.92 ± 0.13      1.17 ± 0.26
  t~1/2z~ (h)            6.50 ± 1.20          2.56 ± 0.17          3.40 ± 0.46        6.52 ± 0.63      2.10 ± 0.37
  AUC~(0-t)~ (µg/L\*h)   11091.22 ± 2824.56   19617.11 ± 2623.90   4295.33 ± 314.81   76.90 ± 14.69    472.64 ± 118.70
  AUC~(0-∞)~ (µg/L\*h)   11620.50 ± 2763.67   19651.18 ± 2634.06   4337.25 ± 325.91   80.41 ± 15.49    480.11 ± 116.51
  MRT~(0-t)~ (h)         5.17 ± 0.34          9.71 ± 0.56          11.42 ± 0.37       4.82 ± 0.76      4.23 ± 0.50
  MRT~(0-∞)~ (h)         6.57 ± 0.95          9.75 ± 0.56          11.65 ± 0.42       6.39 ± 2.22      4.80 ± 0.99
  V~z/F~ (L/kg)          9.36 ± 3.56          2.06 ± 0.29          12.24 ± 1.67       476.8 ± 70.2     150.97 ± 46.98
  CLz/F (L/h/kg)         0.97 ± 0.23          0.56 ± 0.08          2.50 ± 0.18        138.66 ± 27.24   23.60 ± 5.67

###### 

Pharmacokinetic parameters of naringin (NA) and neohesperidin (NHE) after oral administration of monomer, the compatibility of NA-NHE, and FA extract form (mean ± SD, n = 6).

  Parameter              Groups of NA         Groups of NHE                                                                    
  ---------------------- -------------------- -------------------- -------------------- ------------------ ------------------- ----------------------
  C~max~ (µg/L)          2317.25 ± 130.51     2573.79 ± 158.38\*   2448.08 ± 225.62     358.85 ± 14.09     419.73 ± 9.88\*\*   424.89 ± 11.13\*\*
  T~max~ (h)             8.67 ± 1.03          11.33 ± 1.03         9.33 ± 1.03          9.00 ± 1.10        12.00 ± 1.27        9.67 ± 0.82
  t~1/2z~ (h)            2.70 ± 0.23          2.80 ± 0.35          2.56 ± 0.17          4.35 ± 0.81        3.13 ± 0.29         3.40 ± 0.46
  AUC~(0-t)~ (µg/L\*h)   21336.35 ± 2347.74   23670.00 ± 3087.55   19617.11 ± 2623.90   2848.13 ± 395.44   3448.04 ± 552.57    4295.33 ± 314.81\*\*
  AUC~(0-∞)~ (ug/L\*h)   21386.91 ± 2368.44   23776.17 ± 3078.88   19651.18 ± 2634.06   2903.91 ± 396.58   3488.92 ± 571.92    4337.25 ± 325.91
  MRT~(0-t)~ (h)         9.59 ± 0.29          11.48 ± 0.51         9.71 ± 0.56          11.29 ± 0.93       14.60 ± 1.30        11.42 ± 0.37
  MRT~(0-∞)~ (h)         9.65 ± 0.30          11.58 ± 0.52         9.75 ± 0.56          11.88 ± 1.04       14.81 ± 1.40        11.65 ± 0.42
  V~z/F~ (L/kg)          0.34 ± 0.04          0.32 ± 0.06          2.06 ± 0.29          3.96 ± 1.66        2.38 ± 0.31         12.24 ± 1.67
  CLz/F (L/h/kg)         0.09 ± 0.01          0.08 ± 0.01          0.56 ± 0.08          0.63 ± 0.09        0.53 ± 0.10         2.50 ± 0.18

\*P \< 0.05, \*\*P \< 0. 01 for NA-NHE group & FA extract group vs monomer group.

![Comparison of C~max~ and AUC~(0-t)~ of naringin (NA) and neohesperidin (NHE) after oral administration of monomer (NA or NHE), the compatibility (NA-NHE), and FA extract (FA) form. (mean ± SD, n = 6). \**P* \< 0.05, \*\**P* \< 0. 01 for NA-NHE group & FA extract group *vs* monomer group.](fphar-11-00933-g004){#f4}

Discussion {#s4}
==========

UPLC-MS/MS is a powerful analytical tool for the trace compounds in biosamples with high selectivity and sensitivity ([@B36]). Various influencing factors were investigated carefully including separation and detection conditions in this work, and the optimal analytical parameters were obtained for the studied analytes. In addition, the mass spectrometer can be switched freely between ESI (Electro-spray Ionization) +/- detection modes in a single injection, and it ensures that each analyte can get the best response. Therefore, the developed method achieved higher sensitivity than the literatures did with lower LODs (see [**Table 2**](#T2){ref-type="table"}).

A study ([@B29]) has reported that flavone glycosides (naringin, hesperidin, and neohesperidin) could not been detected in the rat plasma even after orally administering 30 g/kg FA decoction, which might be associated with the hydrolysis caused by microbial bacterial from the gastrointestinal tract ([@B6]). Naringin can be quickly absorbed, and metabolized into its aglycone and naringenin glucuronide. Hesperidin was also quickly transferred to hesperetin due to the similar structure ([@B7]; [@B29]). In general, naringin and hesperidin are hydrolyzed in the gastrointestinal tract by the enzymes of intestinal bacteria followed by absorption and conjugation of their aglycones, and the main present forms are naringenin and hesperitin glucuronide/sulfatase conjugations and a small amount of the free aglycones in plasma ([@B32]). Therefore, the concentration of naringin and neohesperidin in mouse plasma were expressed respectively by the total (free + conjugated) concentration of naringenin and hesperitin which was determined by UPLC-MS/MS after hydrolysis with *β*-glucuronidase and sulfatase in this work.

As shown in [**Figure 3**](#f3){ref-type="fig"}, the change trend in concentration-time profiles of naringenin and hesperetin are basically consistent with previous reports ([@B31]; [@B27]; [@B32]): both had double peaks. The double-peak phenomenon may be due to the enterohepatic circulation and drug reabsorption of naringin and neohesperidin in rats, which was also reported for other flavonoid glycosides from the extract of TCM ([@B17]; [@B16]; [@B38]; [@B19]). In addition, these components can be detected in rat plasma within 5 min after dosing with a short T~max~ (less than 1 h), and which indicates that they be absorbed easily and rapidly after oral administration. The values of C~max~ and AUC of naringenin and hesperitin are relatively big, which indicates their bioavailability is not as low as reported in the literatures ([@B17]). The metabolic behaviors of the flavonoid glycosides might also be explained by the enterohepatic circulation or multiple site absorption ([@B28]). Meanwhile, the double-peak phenomenon and the so-called low bioavailability might also suggest that the reabsorption of the metabolites secreted in bile for FA should be more obvious.

Meranzin hydrate and meranzin, as the typical coumarins, were absorbed rapidly (T~max~, about 1 h) but eliminated slowly (t~1/2z~ exceeds 6.5 h). Nobiletin, a polymethoxy flavone, was also rapidly absorbed with T~max~ value of 1.17 ± 0.26 h and AUC~(0-t)~ value of 472.64 ± 118.70, which was consistent with the previous report ([@B20]; [@B26]). The average t~1/2z~ of nobiletin was 2.10 ± 0.37 h in rats, suggested that nobiletin should be rapidly distributed and eliminated ([@B26]), which was partly different from the previous report, probably owing to the interactions among components in FA extract ([@B23]; [@B39]).

Statistical moment analysis (corresponding to non-compartmental model) and compartmental model analysis can be simultaneously performed in a run of batch analysis by DAS 3.1. In the current *in vivo* data analysis, the non-compartmental model has become the mainstream processing method and has been recommended by the drug review authorities in various countries ([@B36]; [@B32]). In particular, the statistical moment analysis is more reliable for the drugs with double-peak phenomena. In this work, naringenin and hesperetin are found to have exactly these pharmacokinetic properties. So, the statistical moment parameters are shown in [**Tables 6**](#T6){ref-type="table"} and [**7**](#T7){ref-type="table"}. In the compartmental model analysis, various models and different statistical weights were compared in this work, and two-compartment parameters were found to be the optimal fitting values with the minimum AIC (Akaike\'s Information Criterion) and the best R (correlation coefficient) values ([@B36]; [@B34]). The compartmental model parameters are shown in [**Tables S1**](#ST1){ref-type="supplementary-material"} and [**S2**](#ST2){ref-type="supplementary-material"}.

As mentioned above, the pharmacokinetic characteristics of naringenin and hespeietin are closely related with enterohepatic circulation or multiple site absorption/reabsorption, which indicates their pharmacokinetics may be affected by the forms in which they exist. Therefore, we design the following four groups to investigate the effects: pure monomer (naringenin and hesperitin), compatibility (NA-NHE), and FA extract group. The results demonstrated that there were significant differences in pharmacokinetic parameters between different drug forms, including AUC~(0--t)~, AUC~(0--∞)~, C~max~, t~max~, t~1/2z~, and CL~Z/F~. The main differences were observed between the compatibility group and the other two groups: ① remarkable increases in the values of AUC~(0--∞)~, AUC~(0--t)~ and C~max~; ② obvious decrease of CL~Z/F~; and ③ longer t~max~ and t~1/2z~. The comparisons of C~max~ and AUC~(0--t)~ between different groups were shown in [**Figure 4**](#f4){ref-type="fig"}. The results suggest that compatibility can promote mutual absorption and affect the metabolic behaviors. Drug-drug interactions often occur, and the detailed effect of compatibility on the pharmacokinetics needs further study.

Conclusion {#s5}
==========

The proposed UPLC-MS/MS method was suitable for the accurate determination of meranzin hydrate, naringenin, hesperetin, meranzin, and nobiletin in rat plasma with high selectivity and sensitivity. The analytical method has been successfully used for the pharmacokinetic studies following oral administration of monomer, drugs in compatibility, and FA extract. The five components in FA can rapidly be absorbed. Drug compatibility can promote mutual absorption and affect the metabolic behaviors.
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